[{"id":"d14f485f-777a-43a1-8203-72839c6c8199","acronym":"","url":"https://clinicaltrials.gov/study/NCT03500991","created_at":"2021-01-18T17:14:31.303Z","updated_at":"2024-07-02T16:35:25.620Z","phase":"Phase 1","brief_title":"HER2-specific CAR T Cell Locoregional Immunotherapy for HER2-positive Recurrent/Refractory Pediatric CNS Tumors","source_id_and_acronym":"NCT03500991","lead_sponsor":"Seattle Children's Hospital","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER2-Specific CAR T"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 07/26/2018","start_date":" 07/26/2018","primary_txt":" Primary completion: 07/26/2024","primary_completion_date":" 07/26/2024","study_txt":" Completion: 07/26/2039","study_completion_date":" 07/26/2039","last_update_posted":"2023-12-20"}]